Diversity in Pharma: Why Risk Minimisation’ Has it all Wrong
Posted on 31/12/2014
The lack of women on pharma boards is well-known, so why are companies still slow to balance the genders? Nick Stephens tells us the problem is “demand, not supply” and why quotas aren’t a simple fix.
By Fiona Barry, 25-Nov-2014